Quince Therapeutics, Inc. announced the online publication of long-term safety data for EryDex in pediatric patients with Ataxia-Telangiectasia (A-T) in the journal Frontiers in Neurology. This post-hoc analysis included data from patients treated for a minimum of 24 months in a Phase 3 clinical trial (ATTeST) and an open-label extension study.
The publication highlighted that adverse events typically associated with prolonged corticosteroid use, such as Cushingoid features, weight gain, hypertension, hirsutism, diabetes, or stunted growth, were rarely reported. This supports the potential of the EryDex System to deliver dexamethasone sodium phosphate encapsulated in red blood cells without the chronic debilitating toxicities seen with standard corticosteroid treatment.
Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, noted that with over 6,000 monthly doses administered to nearly 400 patients over 10-plus years, the company is building a strong safety database. This data is significant as the pivotal Phase 3 NEAT clinical trial continues enrollment, with topline results expected in the fourth quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.